Interferon-γ production by CMV-specific CD8+ T lymphocytes provides protection against cytomegalovirus reactivation in critically ill patients

[1] Kotton CN(2013)Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation Transplantation 96 333-360

[2] Kumar D(2009)Cytomegalovirus in solid organ transplant recipients Am J Transplant 9 S78-S86

[3] Caliendo AM(2015)Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial Ann Intern Med 162 1-10

[4] Asberg A(2009)Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit Crit Care Med 37 2350-2358

[5] Chou S(2011)Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis Crit Care 15 R77-422

[6] Danzinger-Isakov A(2008)Cytomegalovirus reactivation in critically ill immunocompetent patients JAMA 300 413-281

[7] Humar D(2015)Cytomegalovirus reactivation in a general, nonimmunosuppressed intensive care unit population: incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers J Crit Care 30 276-1857

[8] Snydman M(2009)Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients Crit Care Med 37 1850-3314

[9] Boeckh WG(2009)Cytomegalovirus infection in critically ill patients: a systematic review Crit Care 13 R68-3169

[10] Nichols RF(2012)Can we predict cytomegalovirus reactivation in critically ill patients? Crit Care Med 40 3313-98

[1] Kotton CN(2013)Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation Transplantation 96 333-360

[2] Kumar D(2009)Cytomegalovirus in solid organ transplant recipients Am J Transplant 9 S78-S86

[3] Caliendo AM(2015)Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial Ann Intern Med 162 1-10

[4] Asberg A(2009)Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit Crit Care Med 37 2350-2358

[5] Chou S(2011)Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis Crit Care 15 R77-422

[6] Danzinger-Isakov A(2008)Cytomegalovirus reactivation in critically ill immunocompetent patients JAMA 300 413-281

[7] Humar D(2015)Cytomegalovirus reactivation in a general, nonimmunosuppressed intensive care unit population: incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers J Crit Care 30 276-1857

[8] Snydman M(2009)Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients Crit Care Med 37 1850-3314

[9] Boeckh WG(2009)Cytomegalovirus infection in critically ill patients: a systematic review Crit Care 13 R68-3169

[10] Nichols RF(2012)Can we predict cytomegalovirus reactivation in critically ill patients? Crit Care Med 40 3313-98